scholarly journals Breast Density Does Not Influence Breast Cancer Death Among Breast Cancer Patients

2012 ◽  
Vol 104 (16) ◽  
pp. NP-NP
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Density ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Breast Cancer Death

Is Breast Cancer Ever Cured? Follow-Up Study of 5623 Breast Cancer Patients

1991 ◽  
Vol 77 (6) ◽  
pp. 465-467 ◽  
Author(s):  
Stefano Ciatto ◽  
Rita Bonardi
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Disease ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Death Rates ◽  
Breast Cancer Death ◽  
Long Term Follow Up

The authors evaluated 5623 cases of primary breast cancer followed for 1 to 21 years. Overall and breast cancer death rates were determined and compared to expected rates. Breast cancer patients showed overall and breast cancer death rates significantly higher than expected and which persisted at long-term follow-up. The observed/expected overall death ratios for follow-up periods of 0–5, 6–10, 11–15 or 16–20 years were 3.61, 2.55, 1.60 and 2.11, respectively. Death rates from breast cancer at 5, 10, 15 and 20 years were 20%, 32%, 40% and 48% respectively. The evidence of a persistent excess mortality even after long-term follow-up suggests the hypothesis that breast cancer is a systemic disease when clinically diagnosed. This study provided no evidence of a « clinical » cure for breast cancer patients. Even for N- patients the 5, 10, 15 and 20 year death rates from breast cancer were 12%, 20%, 28% and 38%, respectively. N- breast cancer, which is currently considered as a localized disease cured by surgery in most cases, would be better regarded to as a slow-growing metastatic disease, although « personal » cure may be achieved in many subjects dying of causes other than breast cancer.

scholarly journals Imaging Biomarkers as Predictors for Breast Cancer Death

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Wendy Yi-Ying Wu ◽  
Laszlo Tabar ◽  
Tibor Tot ◽  
Ching-Yuan Fann ◽  
Amy Ming-Fang Yen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Treatment Modalities ◽  
Imaging Biomarkers ◽  
Molecular Testing ◽  
Architectural Distortion ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Breast Cancer Death ◽  
Basal Phenotype

Background. To differentiate the risk of breast cancer death in a longitudinal cohort using imaging biomarkers of tumor extent and biology, specifically, the mammographic appearance, basal phenotype, histologic tumor distribution, and conventional tumor attributes.Methods. Using a prospective cohort study design, 498 invasive breast cancer patients diagnosed between 1996 and 1998 were used as the test cohort to assess the independent effects of the imaging biomarkers and other predictors on the risk of breast cancer death. External validation was performed with a cohort of 848 patients diagnosed between 2006 and 2010.Results. Mammographic tumor appearance was an independent predictor of risk of breast cancer death (P=0.0003) when conventional tumor attributes and treatment modalities were controlled. The casting type calcifications and architectural distortion were associated with 3.13-fold and 3.19-fold risks of breast cancer death, respectively. The basal phenotype independently conferred a 2.68-fold risk compared with nonbasal phenotype. The observed deaths did not differ significantly from expected deaths in the validation cohort. The application of imaging biomarkers together with other predictors classified twelve categories of risk for breast cancer death.Conclusion. Combining imaging biomarkers such as the mammographic appearance of the tumor with the histopathologic distribution and basal phenotype, accurately predicted long-term risk of breast cancer death. The information may be relevant for determining the need for molecular testing, planning treatment, and determining the most appropriate clinical surveillance schedule for breast cancer patients.

Genomic stratification with BCI of ER+ early breast cancer patients with limited long-term risk of breast cancer death.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 516-516
Author(s):  
Virginia G. Kaklamani ◽  
Graham M. Poage ◽  
Tommy Fornander ◽  
Bo Nordenskjold ◽  
Olle Stål ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Breast Cancer Death

The non-breast-cancer death rate among breast cancer patients

2010 ◽  
Vol 127 (1) ◽  
pp. 243-249 ◽  
Author(s):  
Devon Bush ◽  
Barbara Smith ◽  
Jerry Younger ◽  
James S. Michaelson
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Death Rate ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Breast Cancer Death ◽  
Cancer Death Rate ◽  
Breast Cancer Death Rate

scholarly journals Immunotherapy and prevention of breast cancer

2020 ◽  
Vol 7 (2) ◽  
pp. 58-70
Author(s):  
Neelam Thacker ◽  
Perianayagam Taneja
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Triple Negative ◽  
Standard Of Care ◽  
Breast Tumors ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Conventional Chemotherapy ◽  
Prevention Of Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

Does breast density affect the ability of MRI to detect mammographically occult cancers?

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 54-54
Author(s):  
Beth Cutler Freedman ◽  
Jocelyn Luongo ◽  
Alyssa Gillego ◽  
Tamara Fulop ◽  
Susan K. Boolbol
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Density ◽  
Retrospective Chart Review ◽  
Breast Mri ◽  
Mammographic Breast Density ◽  
Breast Cancer Patients ◽  
Mri Findings ◽  
Number Of Patients ◽  
Density Methods

54 Background: In breast cancer patients, the use of preoperative MRI is increasing. A change in the operative plan due to MRI findings occurs in 8%-20% of cases. Preoperative MRI is used routinely by many surgeons and radiologists, but debate persists with regard to its indications. We evaluated whether mammographic breast density affected MRI findings. We also examined whether the number of MRI detected synchronous cancers were affected by breast density. Methods: A retrospective chart review was performed of newly diagnosed breast cancer patients who underwent preoperative MRI from 2008-2011. There were three categories of breast density: fat-replaced, scattered fibroglandular densities, and dense. We determined the number of patients in each group who underwent biopsies based on MRI findings, and evaluated the number of occult cancers diagnosed as a result of these biopsies. Results: 301 patients were included. Overall, 64 patients (21%) who underwent an image guided biopsy based on pre-operative breast MRI were diagnosed with an additional focus of cancer. Of the 17 patients with fat-replaced breasts, 4 underwent additional biopsy, and carcinoma was identified in all patients. 149 patients had scattered fibroglandular densities; 53 (36%) underwent additional biopsies. New cancers were diagnosed in 28 patients (19%). Of 135 patients with dense breasts, 61 patients (45%) had additional biopsies, and new cancers were diagnosed in 24 % of these patients. Conclusions: MRI detected additional cancer in 21% of patients in this study. MRI is sensitive and specific in patients with fat-replaced breasts (100%), but due to the small number of patients in this group, additional studies must be done to evaluate the usefulness in this group of patients. We conclude that MRI is useful for detecting additional cancers in patients of all breast densities, and may change the surgical options of the patient when multicentric or contralateral disease is diagnosed.[Table: see text]

scholarly journals Immunotherapy and prevention of breast cancer

2020 ◽  
Vol 7 (2) ◽  
pp. 58-70
Author(s):  
Neelam Thacker ◽  
Perianayagam Taneja
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Triple Negative ◽  
Standard Of Care ◽  
Breast Tumors ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Conventional Chemotherapy ◽  
Prevention Of Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

Sign in / Sign up

Export Citation Format

Share Document